查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402887

女性健康市场 - 全球产业分析、规模、份额、成长、趋势和预测，2023-2031 年

Women's Health Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

女性健康市场 - 报告范围

TMR 关于全球女性健康市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球女性健康市场的收入2017-2031年期间，考虑2023年为基准年，2031年为预测年。报告中也提供了2023年至2031年全球女性健康市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解女性健康市场。

市场概况
2023年市场价值 778 亿美元
2031 年市场价值 1,309 亿美元
CAGR 5.5%

该报告深入探讨了全球女性健康市场的竞争格局。全球女性健康市场的主要参与者已经确定，并且每位参与者都根据不同的属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球女性健康市场参与者的属性。

目录

第 1 章：执行摘要

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 市场区隔
  • 概述
  • 市场动态
  • 2023-2031年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 女性常见健康问题清单
  • 全球主要国家的疾病盛行率和发生率
  • COVID-19 大流行对该行业的影响

第 6 章：市场分析与预测：依治疗类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依治疗类型，2023-2031
    • 荷尔蒙治疗
      • 雌激素治疗
      • 黄体素治疗
      • 联合疗法
      • 甲状腺替代疗法
      • 副甲状腺素治疗
      • 其他的
    • 非荷尔蒙治疗
      • 标靶治疗药物
      • 抗生素
      • 双磷酸盐
      • 其他的
  • 市场吸引力：按治疗类型

第 7 章：全球市场分析与预测：按疾病适应症

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依疾病适应症，2023-2031
    • 癌症
      • 乳癌
      • 子宫颈癌
      • 卵巢癌
    • 甲状腺功能低下症
    • 停经后综合症
    • 骨质疏鬆症
    • 避孕
    • 子宫肌瘤
    • 泌尿道感染
    • 其他的
  • 市场吸引力：依疾病适应症分类

第 8 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2023-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 9 章：北美市场分析与预测

第 10 章：欧洲市场分析与预测

第 11 章：亚太市场分析与预测

第 12 章：拉丁美洲市场分析与预测

第 13 章：中东和非洲市场分析与预测

第 14 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • Eli Lilly and Company
    • Novartis AG
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • Novo Nordisk A/S
    • Amgen Inc.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Allergan Plc.
    • GlaxoSmithKline plc
    • Lupin Pharmaceuticals, Inc.
Product Code: TMRGL214

Women's Health Market - Scope of Report

TMR's report on the global women's health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global women's health market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global women's health market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the women's health market.

Market Snapshot
Market Value in 2023US$ 77.8 Bn
Market Value in 2031US$ 130.9 Bn
CAGR5.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global women's health market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global women's health market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global women's health market.

The report delves into the competitive landscape of the global women's health market. Key players operating in the global women's health market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global women's health market profiled in this report.

Key Questions Answered in Global women's health Market Report:

  • What is the sales/revenue generated by women's health across all regions during the forecast period?
  • What are the opportunities in the global women's health market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Women's Health Market - Research Objectives and Research Approach

The comprehensive report on the global women's health market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global women's health market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global women's health market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Women's Health Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Women's Health Market Analysis and Forecast, 2023-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. List of Common Health Issues Among Women
  • 5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Women's Health Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2023-2031
    • 6.3.1. Hormonal Treatment
      • 6.3.1.1. Estrogen Therapy
      • 6.3.1.2. Progestin Therapy
      • 6.3.1.3. Combination Therapy
      • 6.3.1.4. Thyroid Replacement Therapy
      • 6.3.1.5. Parathyroid Hormone Therapy
      • 6.3.1.6. Others
    • 6.3.2. Non-Hormonal Treatment
      • 6.3.2.1. Targeted Therapy Drugs
      • 6.3.2.2. Antibiotics
      • 6.3.2.3. Bisphosphonates
      • 6.3.2.4. Others
  • 6.4. Market Attractiveness, by Treatment Type

7. Global Women's Health Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 7.3.1. Cancer
      • 7.3.1.1. Breast Cancer
      • 7.3.1.2. Cervical Cancer
      • 7.3.1.3. Ovarian Cancer
    • 7.3.2. Hypothyroidism
    • 7.3.3. Post-Menopausal Syndrome
    • 7.3.4. Osteoporosis
    • 7.3.5. Contraception
    • 7.3.6. Uterine Fibroid
    • 7.3.7. Urinary Tract Infection
    • 7.3.8. Others
  • 7.4. Market Attractiveness, by Disease Indication

8. Global Women's Health Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2023-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Women's Health Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 9.2.1. Hormonal Treatment
      • 9.2.1.1. Estrogen Therapy
      • 9.2.1.2. Progestin Therapy
      • 9.2.1.3. Combination Therapy
      • 9.2.1.4. Thyroid Replacement Therapy
      • 9.2.1.5. Parathyroid Hormone Therapy
      • 9.2.1.6. Others
    • 9.2.2. Non-Hormonal Treatment
      • 9.2.2.1. Targeted Therapy Drugs
      • 9.2.2.2. Antibiotics
      • 9.2.2.3. Bisphosphonates
      • 9.2.2.4. Others
  • 9.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 9.3.1. Cancer
      • 9.3.1.1. Breast Cancer
      • 9.3.1.2. Cervical Cancer
      • 9.3.1.3. Ovarian Cancer
    • 9.3.2. Hypothyroidism
    • 9.3.3. Post-Menopausal Syndrome
    • 9.3.4. Osteoporosis
    • 9.3.5. Contraception
    • 9.3.6. Uterine Fibroid
    • 9.3.7. Urinary Tract Infection
    • 9.3.8. Others
  • 9.4. Market Value Forecast, by Country, 2023-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
      • 9.5.1.1. By Treatment Type
      • 9.5.1.2. By Disease Indication
      • 9.5.1.3. By Country

10. Europe Women's Health Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 10.2.1. Hormonal Treatment
      • 10.2.1.1. Estrogen Therapy
      • 10.2.1.2. Progestin Therapy
      • 10.2.1.3. Combination Therapy
      • 10.2.1.4. Thyroid Replacement Therapy
      • 10.2.1.5. Parathyroid Hormone Therapy
      • 10.2.1.6. Others
    • 10.2.2. Non-Hormonal Treatment
      • 10.2.2.1. Targeted Therapy Drugs
      • 10.2.2.2. Antibiotics
      • 10.2.2.3. Bisphosphonates
      • 10.2.2.4. Others
  • 10.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 10.3.1. Cancer
      • 10.3.1.1. Breast Cancer
      • 10.3.1.2. Cervical Cancer
      • 10.3.1.3. Ovarian Cancer
    • 10.3.2. Hypothyroidism
    • 10.3.3. Post-Menopausal Syndrome
    • 10.3.4. Osteoporosis
    • 10.3.5. Contraception
    • 10.3.6. Uterine Fibroid
    • 10.3.7. Urinary Tract Infection
    • 10.3.8. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
      • 10.5.1.1. By Treatment Type
      • 10.5.1.2. By Disease Indication
      • 10.5.1.3. By Country/Sub-region

11. Asia Pacific Women's Health Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 11.2.1. Hormonal Treatment
      • 11.2.1.1. Estrogen Therapy
      • 11.2.1.2. Progestin Therapy
      • 11.2.1.3. Combination Therapy
      • 11.2.1.4. Thyroid Replacement Therapy
      • 11.2.1.5. Parathyroid Hormone Therapy
      • 11.2.1.6. Others
    • 11.2.2. Non-Hormonal Treatment
      • 11.2.2.1. Targeted Therapy Drugs
      • 11.2.2.2. Antibiotics
      • 11.2.2.3. Bisphosphonates
      • 11.2.2.4. Others
  • 11.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 11.3.1. Cancer
      • 11.3.1.1. Breast Cancer
      • 11.3.1.2. Cervical Cancer
      • 11.3.1.3. Ovarian Cancer
    • 11.3.2. Hypothyroidism
    • 11.3.3. Post-Menopausal Syndrome
    • 11.3.4. Osteoporosis
    • 11.3.5. Contraception
    • 11.3.6. Uterine Fibroid
    • 11.3.7. Urinary Tract Infection
    • 11.3.8. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment Type
    • 11.5.2. By Disease Indication
    • 11.5.3. By Country/Sub-region

12. Latin America Women's Health Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 12.2.1. Hormonal Treatment
      • 12.2.1.1. Estrogen Therapy
      • 12.2.1.2. Progestin Therapy
      • 12.2.1.3. Combination Therapy
      • 12.2.1.4. Thyroid Replacement Therapy
      • 12.2.1.5. Parathyroid Hormone Therapy
      • 12.2.1.6. Others
    • 12.2.2. Non-Hormonal Treatment
      • 12.2.2.1. Targeted Therapy Drugs
      • 12.2.2.2. Antibiotics
      • 12.2.2.3. Bisphosphonates
      • 12.2.2.4. Others
  • 12.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 12.3.1. Cancer
      • 12.3.1.1. Breast Cancer
      • 12.3.1.2. Cervical Cancer
      • 12.3.1.3. Ovarian Cancer
    • 12.3.2. Hypothyroidism
    • 12.3.3. Post-Menopausal Syndrome
    • 12.3.4. Osteoporosis
    • 12.3.5. Contraception
    • 12.3.6. Uterine Fibroid
    • 12.3.7. Urinary Tract Infection
    • 12.3.8. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment Type
    • 12.5.2. By Disease Indication
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Women's Health Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 13.2.1. Hormonal Treatment
      • 13.2.1.1. Estrogen Therapy
      • 13.2.1.2. Progestin Therapy
      • 13.2.1.3. Combination Therapy
      • 13.2.1.4. Thyroid Replacement Therapy
      • 13.2.1.5. Parathyroid Hormone Therapy
      • 13.2.1.6. Others
    • 13.2.2. Non-Hormonal Treatment
      • 13.2.2.1. Targeted Therapy Drugs
      • 13.2.2.2. Antibiotics
      • 13.2.2.3. Bisphosphonates
      • 13.2.2.4. Others
  • 13.3. Market Value Forecast, by Disease Indication, 2023-2031
    • 13.3.1. Cancer
      • 13.3.1.1. Breast Cancer
      • 13.3.1.2. Cervical Cancer
      • 13.3.1.3. Ovarian Cancer
    • 13.3.2. Hypothyroidism
    • 13.3.3. Post-Menopausal Syndrome
    • 13.3.4. Osteoporosis
    • 13.3.5. Contraception
    • 13.3.6. Uterine Fibroid
    • 13.3.7. Urinary Tract Infection
    • 13.3.8. Others
  • 13.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Treatment Type
    • 13.5.2. By Disease Indication
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Eli Lilly and Company
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Novartis AG
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Pfizer, Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Merck & Co., Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Novo Nordisk A/S
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Amgen Inc.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. AstraZeneca
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. F. Hoffmann-La Roche Ltd
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Sanofi
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Allergan Plc.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. GlaxoSmithKline plc
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. Financial Overview
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Lupin Pharmaceuticals, Inc.
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. Financial Overview
      • 14.3.12.4. SWOT Analysis
      • 14.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 02: Global Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
  • Table 03: Global Women's Health Market Value (US$ Mn) Forecast, by Region, 2023-2031
  • Table 04: North America Women's Health Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 05: North America Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 06: North America Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
  • Table 07: Europe Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 08: Europe Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 09: Europe Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031
  • Table 10: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 11: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 12: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031
  • Table 13: Latin America Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Latin America Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 15: Latin America Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031
  • Table 16: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 17: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 18: Middle East & Africa Women's Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031

List of Figures

  • Figure 01: Global Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 02: Global Women's Health Market Value Share, by Treatment Type, 2022
  • Figure 03: Global Women's Health Market Value Share, by Disease Indication, 2022
  • Figure 04: Global Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 05: Global Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 06: Global Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 07: Global Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 08: Global Women's Health Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 09: Global Women's Health Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 10: North America Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 11: North America Women's Health Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 12: North America Women's Health Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 13: North America Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 14: North America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 15: North America Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 16: North America Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 17: Europe Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 18: Europe Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 19: Europe Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 20: Europe Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 21: Europe America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 22: Europe Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 23: Europe Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 24: Asia Pacific Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 25: Asia Pacific Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 26: Asia Pacific Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Asia Pacific Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 28: Asia Pacific America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 29: Asia Pacific Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 30: Asia Pacific Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 31: Latin America Women's Health Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 32: Latin America Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Latin America Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Latin America Women's Health Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 35: Latin America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 36: Middle East & Africa Women's Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 37: Middle East & Africa Women's Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Middle East & Africa America Women's Health Market Value Share Analysis, by Treatment Type, 2023-2031
  • Figure 39: Middle East & Africa America Women's Health Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 40: Middle East & Africa Women's Health Market Value Share Analysis, by Disease Indication, 2022 and 2031
  • Figure 41: Middle East & Africa Women's Health Market Attractiveness Analysis, by Disease Indication 2023-2031
  • Figure 42: Global Women's Health Market Share Analysis, by Company (2022)